Microsoft Word - RadBio_Programme_ParisSept2017_verAug31

1516-1517 / 2063

Efficacy
Bonner Lancet Oncol 2010
3y OS rate: 55.0% vs 45.0% (p=0.05)
5y OS rate: 45.6% vs 36.4% (p<0.05)
• Cetuximab+RT improves OS compared with RT